Cancer of unknown primary site: Missing primary or missing biology?

Oncologist

Volumn 12, Issue 4, 2007, Pages 418-425

  Pentheroudakis, George ^a   Briasoulis, Evangelos ^a   Pavlidis, Nicholas ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Cancer; Molecular biology; Unknown primary

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOPROTEIN; STEM CELL FACTOR RECEPTOR;

ANGIOGENESIS; CANCER LOCALIZATION; CANCER OF UNKNOWN PRIMARY SITE; CARCINOGENESIS; CHROMOSOME ABERRATION; CLINICAL FEATURE; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; KARYOTYPING; METASTASIS; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR SUPPRESSOR GENE;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS, UNKNOWN PRIMARY; ONCOGENES;

EID: 34247869752     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-4-418     Document Type: Review

References (40)

1. Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol 2005;54:243-250.
2. Levi F, Te VC, Erler G et al. Epidemiology of unknown primary tumours. Eur J Cancer 2002;38:1810-1812.
3. Van de Wouw AJ, Jansen RL, Speel EJ et al. The unknown biology of the unknown primary tumour: A literature review. Ann Oncol 2003;14:191-196.
4. Pavlidis N, Briasoulis E, Hainsworth J et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003;39:1990-2005.
5. Mousseau M, Schaerer R, Lutz JM et al. [Hepatic metastasis of unknown primary site.] Bull Cancer 1991;78:725-736. French.
6. Kolesnikov-Gauthier H, Levy E, Merlet P et al. FDG PET in patients with cancer of an unknown primary. Nucl Med Commun 2005;26:1059-1066.
7. Nystrom JS, Weiner JM, Heffelfinger-Juttner J et al. Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 1977;4:53-58.
8. Le Chevalier T, Cvitkovic E, Caille P et al. Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med 1988;148:2035-2039.
9. Pentheroudakis G, Briasoulis E, Karavasilis V et al. Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: Active, but how effective? Acta Oncol 2005;44:155-160.
10. Jallepalli PV, Lengauer C. Chromosome segregation and cancer: Cutting through the mystery. Nat Rev Cancer 2001;1:109-117.
11. Hedley DW, Leary JA, Kirsten F. Metastatic adenocarcinoma of unknown primary site: Abnormalities of cellular DNA content and survival. Eur J Cancer Clin Oncol 1985;21:185-189.
12. Abbruzzese JL, Lenzi R, Raber MN et al. The biology of unknown primary tumors. Semin Oncol 1993;20:238 -243.
13. Motzer RJ, Rodriguez E, Reuter VE et al. Genetic analysis as an aid in diagnosis for patients with midline carcinomas of uncertain histologies. J Natl Cancer Inst 1991;83:341-346.
14. Wessendorf S, Fritz B, Wrobel G et al. Automated screening for genomic imbalances using matrix-based comparative genomic hybridization. Lab Invest 2002;82:47-60.
15. Pavlidis N, Briasoulis E, Bai M et al. Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin. Anticancer Res 1995;15:2563-2567.
16. Hainsworth JD, Lennington WJ, Greco FA. Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. J Clin Oncol 2000;18:632-635.
17. Fizazi K, Voigt JJ, Lesimple T et al. Carcinoma of unknown primary (CUP): Are the tyrosine kinase receptors HER-2, EGF-R, and c-Kit suitable targets for therapy? Proc Am Soc Clin Oncol 2003;22:3549.
18. Rashid A, Hess KR, Lenzi R et al. Overexpression and prevalence of molecular markers in patients with cancer of unknown primary (CUP). Proc Am Soc Clin Oncol 2005;24:9683.
19. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-2459.
20. Dova L, Georgiou I, Vartholomatos G et al. EGFR and C-KIT/CD117 gene mutational screening and oncoprotein expression in patients with cancer of unknown primary: Implications for molecular pathophysiology and therapy. Eur J Cancer 2005;3:424.
21. Debiec-Rychter M, Dumez H, Judson I et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689-695.
22. Briasoulis E, Tsokos M, Fountzilas G et al. Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: Biological and clinical implications. A Hellenic Cooperative Oncology Group study. Anticancer Res 1998;18:1907-1914.
23. Hollstein M, Sidransky D, Vogelstein B et al. p53 mutations in human cancers. Science 1991;253:49 -53.
24. Van de Wouw AJ, Jansen RL, Griffioen AW et al. Clinical and immuno-histochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. Anticancer Res 2004;24:297-301.
25. Bar-Eli M, Abbruzzese JL, Lee-Jackson D et al. p53 gene mutation spectrum in human unknown primary tumors. Anticancer Res 1993;13:1619-1623.
26. Vousden KH, Woude GF. The ins and outs of p53. Nat Cell Biol 2000;2:E178-E180.
27. Yoshida BA, Sokoloff MM, Welch DR et al. Metastasis-suppressor genes: A review and perspective on an emerging field. J Natl Cancer Inst 2000;92:1717-1730.
28. Navenot JM, Wang Z, Chopin M et al. Kisspeptin-10-induced signaling of GPR54 negatively regulates chemotactic responses mediated by CXCR4: Apotential mechanism for the metastasis suppressor activity of kisspeptins. Cancer Res 2005;65:10450-10456.
29. Dova L, Golfinopoulos V, Pentheroudakis G et al. The metastatic potential of cancer of unknown primary is independent of the KiSS-1 metastasis-suppressor gene: A study of 50 patients. Forum of Clinical Oncology 2006;1:Abstract EA23.
30. Naresh KN. Do metastatic tumours from an unknown primary reflect angiogenic incompetence of the tumour at the primary site? - a hypothesis. Med Hypotheses 2002;59:357-360.
31. Hillen HF, Hak LE, Joosten-Achjanie SR et al. Microvessel density in unknown primary tumors. Int J Cancer 1997;74:81-85.
32. Karavasilis V, Malamou-Mitsi V, Briasoulis E et al. Angiogenesis in cancer of unknown primary: Clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer 2005;5:25-32.
33. Karavasilis V, Malamou-Mitsi V, Briasoulis E et al. Matrix metalloproteinases in carcinoma of unknown primary. Cancer 2005;104:2282-2287.
34. Dennis JL, Vass JK, Wit EC et al. Identification from public data of molecular markers of adenocarcinoma characteristic of the site of origin. Cancer Res 2002;62:5999-6005.
35. Su AI, Welsh JB, Sapinoso LM et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001;61:7388-7393.
36. Bloom G, Yang IV, Boulware D et al. Multi-platform, multi-site, microarray-based human tumor classification. Am J Pathol 2004;164:9-16.
37. Tothill RW, Kowalczyk A, Rischin D et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 2005;65:4031-4040.
38. Dennis JL, Hvidsten TR, Wit EC et al. Markers of adenocarcinoma characteristic of the site of origin: Development of a diagnostic algorithm. Clin Cancer Res 2005;11:3766 -3772.
39. Ramaswamy S, Tamayo P, Rifkin R et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A 2001;98:15149-15154.
40. Ma XJ, Patel R, Wang X et al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med 2006;130:465-473.